Aclidinium bromide/formoterol fumarate fixed-dose combination for the treatment of chronic obstructive pulmonary disease

Bibliography

• O'Reilly J, Jones MM, Parnham J, Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated. NICE guidance. BMJ 2010;340:c3134
   PubMedGoogle Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease. Revised 2011. Available from: http://www.goldcopd.com [Last accessed 23 December 2012]
   Google Scholar
• Rodrigo GJ, Plaza V, Castro-Rodriguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012;25:40-7
   PubMed Web of Science ®Google Scholar
• Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonist in COPD. Pulm Pharmacol Ther 2010;23:257-67
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. Beta2-adrenoceptor agonists: current and future direction. Br J Pharmacol 2011;163:4-17
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev 2012;64:450-504
   PubMed Web of Science ®Google Scholar
• Yu AP, Guerin A, de Leon DP, Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respir Med 2011;105:1861-71
   PubMed Web of Science ®Google Scholar
• Yu AP, Guerin A, Ponce de Leon D, Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ 2011;14:486-96
   PubMedGoogle Scholar
• Cazzola M, Segreti A, Bettoncelli G, Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008. Prim Care Respir J 2011;20:291-8
   PubMedGoogle Scholar
• Rutten-van Molken MP, Goossens LM. Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues. Pharmacoeconomics 2012;30:271-302
   PubMed Web of Science ®Google Scholar
• Kozma CM, Paris AL, Plauschinat CA, Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study. BMC Pulm Med 2011;11:61
   PubMed Web of Science ®Google Scholar
• Anonymous. Global Markets for Asthma and COPD Drugs to hit $47 Billion in 2017. Available from: www.marketwatch.com/story/global-markets-for-asthma-copd-drugs-to-hit-47-billion-in-2017-2012-08-21 [Last accessed 7 October, 2012]
   Google Scholar
• Kessler R, Partridge MR, Miravitlles M, Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011;37:264-72
   PubMed Web of Science ®Google Scholar
• Cazzola M, Tashkin DP. Combination of formoterol and tiotropium in the treatment of COPD: effects on lung function. COPD 2009;6:404-15
   PubMedGoogle Scholar
• Matera MG, Page CP, Cazzola M. Novel bronchodilators for the treatment of chronic obstructive pulmonary disease. Trends Pharmacol Sci 2011;32:495-506
   PubMed Web of Science ®Google Scholar
• Sentellas S, Ramos I, Alberti J, Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites. Eur J Pharm Sci 2010;39:283-90
   PubMed Web of Science ®Google Scholar
• Jansat JM, Lamarca R, de Miquel G, Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. J Clin Pharmacol 2009;49:1239-46
   PubMed Web of Science ®Google Scholar
• Jones PW, Singh D, Bateman ED, Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012;40:830-6
   PubMed Web of Science ®Google Scholar
• Cazzola M, Rogliani P, Segreti A, Matera MG. An update on bronchodilators in Phase I and II clinical trials. Expert Opin Investig Drugs 2012;21:1489-50
   PubMed Web of Science ®Google Scholar
• Anonymous. Almirall starts Phase III for aclidinium and formoterol in COPD. Available from: www.almirall.com/webcorp2/contentFiles/1596/en/AB+For_Phase_III_press_release_final.pdf [Last accessed 7 October, 2012]
   Google Scholar
• Sliwinski P, Perng D-W, Chuchalin A, Jones PW. Efficacy and safety of once-daily aclidinium bromide 200 mug in combination with formoterol in patients with COPD (abstract). Thorax 2010;65:A136
   Web of Science ®Google Scholar
• Magnussen H, Watz H, Kretschmar G, Pharmakokinetik, Sicherheit und Aktivitat von formoterol verabreicht uber den Genuair Inhalator® mit und ohne Aclidinium-Bromid (Abstract). Pneumologie 2011;65:V446
   Google Scholar
• UK Medicines Information (UKMI). New Drugs Online Report for aclidinium bromide + formoterol fumarate. Available from: www.ukmi.nhs.uk/applications/ndo/record_view_open.asp?newDrugID=5527 [Last accessed 7 October, 2012]
   Google Scholar
• Cazzola M, Matera MG, Donner CF. Inhaled beta2-adrenoceptor agonists: cardiovascular safety in patients with obstructive lung disease. Drugs 2005;65:1595-610
   PubMed Web of Science ®Google Scholar
• Cazzola M, Calzetta L, Matera MG. The cardiovascular risk of tiotropium: is it real? Expert Opin Drug Saf 2010;9:783-92
   PubMed Web of Science ®Google Scholar
• Gavalda A, Vinyals M, Aubets J, Gra J. Effect of formoterol alone and in combination with aclidinium on electrocardiograms in dogs (abstract). ERS Annual Congress, Vienna 2012. Available from: www.ers-education.org/pages/default.aspx?id=2828&idBrowse=120660&det=1 [Last accessed 7 October, 2012]
   Google Scholar
• Cazzola M, Matera MG. The effective treatment of COPD: anticholinergics and what else? Drug Discov Today Ther Strateg 2006;3:277-86
   Google Scholar
• Qaseem A, Wilt TJ, Weinberger SE, Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011;155:179-91
   PubMed Web of Science ®Google Scholar
• Puffer A. U.S. physician and payer attitudes to novel and me-too fixed dose combination inhalers for asthma and chronic obstructive pulmonary disease. Available from: http://decisionresources.com/Products-and-Services/Report?r=pforus0712 [Last accessed 7 October 2012]
   Google Scholar
• Cazzola M, Brusasco V, Centanni S, Project PriMo: sharing principles and practices of bronchodilator therapy monitoring in COPD: a consensus initiative for optimizing therapeutic appropriateness among Italian specialists. Pulm Pharmacol Ther 2012; doi: 10.1016/j.pupt.2012.10.010
   Web of Science ®Google Scholar
• Agusti A, Hedner J, Marin JM, Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011;20:183-94
   PubMedGoogle Scholar
• Miles MC, Donohue JF, Ohar JA. Optimum bronchodilator combinations in chronic obstructive pulmonary disease: what is the current evidence? Drugs 2012;72:301-8
   PubMed Web of Science ®Google Scholar
• van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012;21:101-8
   PubMedGoogle Scholar
• Cazzola M, MacNee W, Martinez FJ, Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-69
   PubMed Web of Science ®Google Scholar